Zymeworks (NasdaqGS:ZYME) FY Earnings Call Presentation

Financial Highlights - The company anticipates near-term milestones of up to $440 million for global GEA approvals[12] - The company has received $400 million in upfront and milestone payments to date[12] - Future potential regulatory and commercial milestones are valued at $13 billion[12] - Ziihera has a peak sales potential of over $20 billion[12] - The company reported revenues of $103 million for 2025[27] Pipeline and Partnerships - The company has potential future milestone payments of up to $434 million with Phase 3 partners[16] - The company has potential future milestone payments of up to $11 billion with Phase 1 partners[16] - The company has potential future milestone payments of up to $313 million with Phase 1 partners[16] - The company has potential future milestone payments of up to $230 million with Preclinical partners[16] Strategic Outlook - The company's cash resources of over $270 million provide a runway beyond 2028[27]